3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Conditions
Colorectal Neoplasms
50
Neoplasms
13
Neoplasm Metastasis
12
Gastrointestinal Stromal Tumors
10
Carcinoma, Hepatocellular
7
Glioblastoma
5
Colonic Neoplasms
5
Sarcoma
4
Stomach Neoplasms
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Ovarian Neoplasms
3
Liver Neoplasms
3
Rhabdomyosarcoma
2
Rectal Neoplasms
2
Pancreatic Neoplasms
2
Gallbladder Neoplasms
2
Esophageal Neoplasms
2
Colorectal Cancer Metastatic
2
Cholangiocarcinoma
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Bile Duct Neoplasms
2
Advanced Cancer
2
Wilms Tumor
1
Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer)
1
Thymoma
1
Squamous Cell Carcinoma of Head and Neck
1
Somatostatinoma
1
Solid Tumor
1
Sarcoma, Ewing
1
Interventions
COVID-19 Vaccines
4
Blood Specimen Collection
4
Surveys and Questionnaires
3
Standard of Care
3
2019-nCoV Vaccine mRNA-1273
3
Pandemic Preparedness
2
sotrovimab
1
sinovac COVID-19 vaccine
1
selinexor
1
regorafenib
1
proxalutamide
1
monalizumab
1
lenzilumab
1
ciclesonide
1
bemcentinib
1
avdoralimab
1
acalabrutinib
1
XAV-19
1
Surgical Procedures, Operative
1
Sperm Count
1
Specimen Handling
1
Sorafenib
1
Sodium Chloride
1
Rabeprazole
1
Patient Reported Outcome Measures
1
Observation
1
Nutritional Status
1
Niclosamide
1
Meopa
1
Mastectomy, Segmental
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
COVID-19
×
regorafenib
×
Clear all
NCT05594147
2023-11-07
ROCURS
Bayer
Completed
4,103 enrolled